The predictability of response criteria remains controversial in drug development. Numerous reviews and meta-analyses continue to question the reliability of classic surrogate endpoints in predicting patient survival or quality of life to a given therapeutic strategy or intervention in the current era of precision oncology.
Co-chaired by VHIO’s Elena Garralda and ESMO Past-President Solange Peters, Lausanne (Switzerland), a Special Session during last week’s Targeted Anticancer Therapies Congress focused on surrogate endpoints in early phase drug development including novel contenders circulating tumor DNA (ctDNA), pathologic complete response (PCR), and minimal residual disease (MRD).
In her latest On target column, published by ESMO’s Daily Reporter, Elena considers the promise of ctDNA in more strongly predicting clinical outcomes and briefly reviews next steps toward its proper validation and integration as a complementary tool to potentiate current surrogates in early phase drug development, as well as existing response criteria.
To discover more, we invite you to read her latest column here. To browse all previous editions of On target please click here.
Elena Garralda is Executive Director of VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, Principal Investigator of our Early Clinical Drug Development Group, and co-Director of VHIO’s Clinical Research Program.
###
